TechBio is a new branch of the biopharma industry that is focused on creating large, robust, highly structured biological and chemical datasets to fuel advanced computation and improve the hit rate in drug discovery. TechBio companies use data and AI – via in silico modeling – to determine which hypotheses and drug candidates to test in an unbiased fashion. These tests then generate even more data that can be used to make even better predictions.
We believe these companies that have technology at their core will create step-function shifts in the healthcare industry. We believe Recursion is both leading this new sector, and working hard to help define it.
Recursion is an end-to-end AI drug discovery and development company, leading a new sector of biopharma called TechBio. Recursion’s mission is to “decode biology to radically improve lives.” We’re using our automated labs to generate one of the largest biological and chemical datasets in the world, and developing industry-leading machine learning models to uncover new therapeutic targets, precision-design new medicines, and discover biomarkers to match those drugs with the right patients.
Unlike traditional pharma, Recursion’s approach is disease-agnostic. Instead of looking at a specific disease area, gene target, or protein, Recursion uses its platform – the Recursion Operating System (Recursion OS) to search its massive dataset using proprietary machine learning models spanning biology and chemistry to identify relationships and elevate the most promising therapeutic opportunities. This approach allows us to explore lesser known areas of disease biology, and difficult-to-treat targets. Our precision chemistry capabilities allow us to then develop new drug candidates with 10x the efficiency and twice the speed of traditional pharma. As these drugs advance into the clinic, our AI-enabled platform helps us identify the right patient populations and find those patients.
Recursion has:
Recursion has numerous clinical-stage programs spanning oncology and, rare disease:
Recursion partners fit into two categories: therapeutic partners, or and data, technology and capability partners
The Recursion Operating System, or Recursion OS, is Recursion’s proprietary, AI-enabled end-to-end platform for drug discovery and development — an interconnected set of technical and scientific tools spanning physical experimentation to in silico analysis. The Recursion OS unites intelligent machine learning models across data modalities to generate novel therapeutic insights.
Yes! Recursion has open-sourced 65 datasets (Rxrx1, Rxrx2, Rxrx19a, 1Rxrx19b, Rxrx3, and Rxrx3core) and its OpenPhenom-S/16 model (available on Google Cloud’s Model Garden and on HuggingFace) for non-commercial use.
Boltz-2, developed with MIT, is an open-source model that is the first to combine structure and binding affinity prediction, and approaches the accuracy of physics-based free energy perturbation (FEP) calculations while being over 1,000 times faster and less computationally expensive. We also released a related open-source SynFlowNet-Boltz trainer, enabling researchers to to find diverse, synthesizable, high-affinity binders.
EXPLORE RECURSION’S OPEN-SOURCE DATA AND MODELS AT RXRX.AI
Yes, Recursion leveraged our data to identify and screen small libraries of reference and approved compounds to identify potential SARS-CoV-2 therapeutics. Several chemical classes of compounds were identified, based on their ability to reverse viral or cytokine storm-induced phenotypic effects in disease-relevant human cells. Some of the compounds we tested were also evaluated in clinical trials, showing that we correctly predicted 9/10 outcomes for these potential COVID-19 treatments.
